SGN-40 + bortezomib

SGN-40 + bortezomib is an **investigational combination therapy** using the monoclonal antibody SGN-40 (dacetuzumab, a humanized anti-CD40 antibody) and the small molecule proteasome inhibitor bortezomib (marketed as Velcade) for the treatment of **relapsed or refractory multiple myeloma**. - **SGN-40** (dacetuzumab) targets and binds CD40, a costimulatory protein found on antigen-presenting cells and many B-cell malignancies, promoting cell death through immune-mediated mechanisms. - **Bortezomib** is a reversible inhibitor of the 26S proteasome, leading to disruption of protein homeostasis, induction of apoptosis, and inhibition of NF-κB signaling pathways. The rationale for the combination is that targeting different mechanisms—CD40-mediated immune modulation and proteasome inhibition—may provide **additive or synergistic antitumor activity** in treating resistant or relapsed multiple myeloma. The combination has completed early-phase clinical trials evaluating safety, tolerability, and pharmacologic activity in relapsed or refractory multiple myeloma patients[1][3][5][6].

Brand names

Velcade

Other names

SGN-40 + bortezomibdacetuzumab + bortezomib